Navigation Links
CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Date:10/23/2007

Preclinical Studies of Valecor Platinum(TM) Coronary Stent System Indicate Positive Results and Improvements Compared to Market-Leading Bare Stent

BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary results of its recent preclinical studies for CorNova's Valecor Platinum(TM) Coronary Stent System at the TCT 2007 conference in Washington, D.C. The independently-conducted preclinical studies illustrated what CorNova believes to be meaningful improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when compared to a market-leading bare stent in rabbit and porcine models.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO )

Commenting on today's announcement, Dr. Ryan stated, "We are very pleased with the results from these preclinical studies of our Valecor Platinum(TM) Stent, which is designed to maximize biocompatibility while minimizing arterial injury, potentially providing both short and long-term benefits over current bare stent technology. We also believe our Valecor Platinum(TM) Stent may offer the potential of improving coronary stent performance without the need for drug-elution and the inherent risks presented by drug-eluting stents. The Company is proceeding with its efforts to receive CE Mark approval for the Valecor Platinum(TM) Stent and we currently expect to receive that approval in early 2008."

About CorNova

CorNova, Inc., founded in 2003, is a privately-held, development-stage company with an experienced international team of business, medical, and engineering professionals within the field of interventional cardiology. CorNova's business focus is to build value and opportunity through the utilization of the technologies, expertise, and resources of its international team and partner companies to develop and sell innovative endovascular devices. The Company's strategic partners include Implant Sciences Corporation (Amex: IMX) and CardioTech International, Inc. (Amex: CTE).


'/>"/>
SOURCE CorNova, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... PUNE, India , May 20, 2016 /PRNewswire/ ... Professional Survey Report 2016 to Medical Devices of ... professional and in-depth survey on the current state ... basic overview of the industry like definitions, classifications, ... gives information about manufacturing process like Raw Material ...
(Date:5/20/2016)... India , May 20, 2016 ... - Pipeline Review, H1 2016" market research report ... Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ...
(Date:5/19/2016)... 19, 2016 According to a new market ... Countries, (U.S., Germany , France ... , and Japan )", published by MarketsandMarkets, The ... a CAGR of 13.9% from 2016 to 2021.      ... market data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... On the ... took the time to summarize the weight loss process: , New patients have a ... Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There are 15 ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... that, less than 1% of United Kingdom residents who could benefit from bariatric surgery ... Service (NHS) increases the number of bariatric procedures it offers to obese patients from ...
(Date:5/23/2016)... ... May 23, 2016 , ... The ... high-level representatives from the Japan PMDA, US FDA, industry and academia at the ... standards help format data from clinical trials so that it can be shared ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... in research on discriminated minorities’ quality of life and is currently focusing on ... creating advocacy documentaries to be tested through research to find out whether watching ...
Breaking Medicine News(10 mins):